Hims Hers Health

Hims Hers Health

Yahoo Finance • 2 days ago

Most and least shorted mid- to mega-cap healthcare stocks at the end of October

Short interest data from late October 2026 highlights deeply divided investor sentiment across the healthcare sector. Strong bearish bets remain heavily concentrated in high-volatility biotechnology, equipment, and digital health names, wi... Full story

Yahoo Finance • 11 days ago

What Bears Saw Before Hims & Hers Health Slid

If you only glanced at the headlines on Hims & Hers Health, the story looked exciting. AI-native care, GLP-1 partnerships and global expansion sounded like the textbook setup for a win. For Hims & Hers Health shareholders, the loss over th... Full story

Yahoo Finance • 13 days ago

Market Chatter: Hims & Hers Health Bids Judge to Toss Federal Trade Commission Complaint

Hims & Hers Health (HIMS) asked a federal judge in California to toss out a Federal Trade Commission PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 19 days ago

Hims And Hers Health (HIMS) Stock May Trade At A Discount Despite Australia Launch

Hims & Hers Health has been a dramatic ride for shareholders over the past few years, yet recent share price weakness now has investors asking whether the current valuation is still supported by its sales base. With fresh product launches... Full story

Yahoo Finance • 20 days ago

What Does Hims & Hers Health (HIMS) Expansion Into The UK And Australia Mean?

Hims & Hers Health (NYSE:HIMS) announced the launch of Hers personalised hair loss and wellness care in the UK in October 2026. The Hers UK rollout introduces tailored treatment plans for women's hair loss alongside broader wellness servic... Full story

Yahoo Finance • 20 days ago

1 Stock Under $50 with Solid Fundamentals and 2 We Avoid

1 Stock Under $50 with Solid Fundamentals and 2 We Avoid Stocks in the $10-50 range offer a sweet spot between affordability and stability as they're typically more established than penny stocks. But their headline prices don't guarantee... Full story

Yahoo Finance • 21 days ago

Cedar Grove Capital Q3: Adds Zedcor, Auxly; exits MTY, ClearPoint

* Cedar Grove Capital initiated a small tracking position in Zedcor Inc. (ZDC.V) while continuing due diligence and added Auxly Cannabis Group as its first official cannabis investment, citing its growth potential. * The fund also inc... Full story

Yahoo Finance • 24 days ago

Hers Launches in Australia, Built to Care for the Whole Woman

Juniper becomes Hers, bringing new treatments spanning hair regrowth, menopause and perimenopause, and comprehensive weight management SYDNEY, October 12, 2026--(BUSINESS WIRE)--Hims & Hers, the leading global health and wellness platform... Full story

Yahoo Finance • 27 days ago

1 Healthcare Stock Worth Your Attention and 2 We Turn Down

1 Healthcare Stock Worth Your Attention and 2 We Turn Down From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong fin... Full story

Yahoo Finance • last month

Most shorted stocks on Wall Street

[short sale] abluecup As October begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 39 stocks with short interest above 20% of shares outstan... Full story

Yahoo Finance • last month

2 Reasons to Like HIMS (and 1 Not So Much)

2 Reasons to Like HIMS (and 1 Not So Much) The past six months have been a windfall for Hims & Hers Health's shareholders. The company's stock price has jumped 40.2%, hitting $29.23 per share. This was partly due to its solid quarterly re... Full story

Yahoo Finance • last month

Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges

Key Points Interested in Quest Diagnostics Incorporated? Here are five stocks we like better. Quest Diagnostics is outperforming its growth targets: Revenue increased about 12% and earnings more than 10% in 2025, while 2026 guidance calls... Full story

Yahoo Finance • 2 months ago

Hims & Hers Chief Legal Officer Soleil Boughton Sells 6,236 Shares

Chief Legal Officer Soleil Boughton reported a sale of 6,236 shares of Hims & Hers Health (NYSE:HIMS) in a recent SEC Form 4 filing. Transaction summary Metric Value Shares sold 6,236 Transaction value $173,735 Post-transaction shares (d... Full story

Yahoo Finance • 2 months ago

Catalyst Watch: FOMC blockbuster, Salesforce event, and 24-hour trading talk

[Reciprocal Tariffs] Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY - SEPTEMBER 14 * VOLATILIT... Full story

Yahoo Finance • 2 months ago

JPMorgan cautious on Hims & Hers on GLP-1 transition risk

Investing.com -- JPMorgan revealed Friday that it has started coverage of Hims & Hers Health at Neutral, setting a December 2027 price target of $32 as it weighs the direct-to-consumer health platform's rapid growth against execution risks... Full story

Yahoo Finance • 2 months ago

Why Is Hims & Hers Health (HIMS) Down 7.7% Since Last Earnings Report?

A month has gone by since the last earnings report for Hims & Hers Health, Inc. (HIMS). Shares have lost about 7.7% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend contin... Full story

Yahoo Finance • 2 months ago

HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss

Hims & Hers Health, Inc. HIMS delivered second-quarter 2026 revenue of $753.2 million, up 38.2% year over year and 9.1% above the Zacks Consensus Estimate. Subscriber growth and higher spending per subscriber kept the top line moving highe... Full story

Yahoo Finance • 2 months ago

Reasons to Retain Hims & Hers Stock in Your Portfolio for Now

Hims & Hers Health HIMS has entered the second half of 2026 with strong momentum from weight-loss offerings, international expansion and AI-enabled care. However, gross-margin pressure from changing business mix, regulatory uncertainty sur... Full story

Yahoo Finance • 2 months ago

Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors

Collaboration aims to validate Evotec's proprietary BiTco costimulatory CD2 bispecifics platform in combination with Plectonic's logic-gated DNA-protein immunotherapy technology LOGIBODY® BiTco designed to boost T cell activation by engagi... Full story

Yahoo Finance • 2 months ago

Hims & Hers’ Australia Expansion Adds Growth, But Execution Will Be Key

Hims & Hers Health, Inc. (NYSE:HIMS) has entered Australia, marking its first expansion into the Asia-Pacific market. The move follows its acquisition of Australian digital-health platform Eucalyptus, which includes men's health brand Pilo... Full story